Failing to achieve a nadir prostate‐specific antigen after combined androgen blockade: Predictive factors

Objectives:  To determine the optimal cut‐off of a nadir prostate‐specific antigen (PSA) for prediction of progression within 24 months after combined androgen blockade (CAB) and to analyze predictive factors of failing to achieve the nadir PSA.

[1]  Tomohiko Ichikawa,et al.  Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. , 2008, The Journal of urology.

[2]  T. Deguchi,et al.  Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study , 2008, Journal of Cancer Research and Clinical Oncology.

[3]  Y. Sugimura,et al.  Prostate‐specific antigen half‐life and pretreatment prostate‐specific antigen: Crucial predictors for prostate‐specific antigen trend in delayed‐combined androgen blockade therapy , 2007, International journal of urology : official journal of the Japanese Urological Association.

[4]  C. Tangen,et al.  Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  C. Tangen,et al.  The prognostic value of hemoglobin change after initiating androgen‐deprivation therapy for newly diagnosed metastatic prostate cancer , 2006, Cancer.

[6]  J. Ferlay,et al.  Cancer incidence and mortality in Europe, 2004. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Peter Boyle,et al.  Cancer incidence and mortality in Europe , 2005, Sozial- und Präventivmedizin.

[8]  I. Thompson,et al.  Prognostic value of anemia in newly diagnosed metastatic prostate cancer: a multivariate analysis of southwest oncology group study 8894. , 2004, The Journal of urology.

[9]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[10]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[11]  J. Morote,et al.  Nadir prostate‐specific antigen best predicts the progression to androgen‐independent prostate cancer , 2004, International journal of cancer.

[12]  T. Matsuda,et al.  Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. , 2004, Japanese journal of clinical oncology.

[13]  L. Collette,et al.  Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892). , 2003, European urology.

[14]  F. Dammacco,et al.  Recent Advances in Understanding the Pathogenesis of Anemia in Multiple Myeloma , 2003, International journal of hematology.

[15]  Sang Eun Lee,et al.  Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. , 2002, The Journal of urology.

[16]  A. Renshaw,et al.  Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high‐risk prostate cancer , 2002, Cancer.

[17]  C. Roehrborn,et al.  Gleason score predicts androgen independent progression after androgen deprivation therapy. , 2002, European urology.

[18]  C. Roehrborn,et al.  Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer. , 2002, Urology.

[19]  S. Krantz,et al.  Progress in understanding the pathogenesis of the anemia of chronic disease. , 1992, Blood.

[20]  J. Miller,et al.  The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. , 1992, The Journal of urology.

[21]  E.,et al.  Progress in Understanding the Pathogenesis of the Anemia of Chronic Disease , 1992 .

[22]  L. Denis,et al.  Biochemical monitoring of carcinoma of prostate treated with an LH-RH analogue (Zoladex). , 1986, British journal of urology.

[23]  F W MULSOW,et al.  Cancer incidence and mortality , 2019, Health at a Glance: Europe.